Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Case 2 Presentation: Lower-Risk MDS-RS With an SF3B1 Mutation

February 16th 2023

Dr Cluzeau introduces a second patient case of lower-risk MDS-RS with an SF3B1 mutation and symptomatic anemia, who received a first-line erythropoiesis-stimulating agent (ESA) and second-line luspatercept.

Ponatinib Plus Reduced-Intensity Chemotherapy Steps Up as Potential New SOC in Newly Diagnosed Ph+ ALL

February 15th 2023

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

EPCORE Pushes CD3 × CD20 Bispecific Antibody Into Next Phase of Exploration in DLBCL

February 15th 2023

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

Closing Remarks on Advances and Future Directions in MF and MDS

February 15th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

Acute Myeloid Leukemia: Frontline Treatment With CPX-351

February 14th 2023

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Role of a Pharmacist in Managing Tumor Lysis Syndrome

February 14th 2023

Expert perspective on the role of a pharmacist in managing patients with identified tumor lysis syndrome.

Frontline Treatment Options for Patients With IDH2-Mutated AML

February 14th 2023

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

An Overview on Tumor Lysis Syndrome in Cancer Care

February 14th 2023

Anthony Perissinotti, PharmD, BCOP, highlights associated risk for tumor lysis syndrome and identifies signs and symptoms.

Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

ASH 2022: Recent Advances in Chronic Myeloid Leukemia

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Dr. Kim on the Synergistic Effect of PD-1H Blockade in AML

February 13th 2023

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Annamycin Achieves 80% ORR in Relapsed/Refractory Acute Myeloid Leukemia

February 13th 2023

Topline results from the phase 1 European MB-105 clinical trial showed that new safety results for annamycin, a next-generation anthracycline, are in keeping with previous findings for patients with relapsed/refractory acute myeloid leukemia.

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13th 2023

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

Treatment Options: Steroid-Refractory GvHD

February 10th 2023

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Treatment Options for Chronic GvHD

February 10th 2023

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Brexucabtagene Autoleucel Elicits OS Benefit in Relapsed/Refractory B-ALL

February 9th 2023

The CAR T-cell therapy brexucabtagene autoleucel produced a median overall survival of 26 months in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma

February 9th 2023

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

The Impact of p53 Mutations and 5q Deletions on Lower-Risk MDS Treatment Response

February 9th 2023

Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.

Case 1: Expert Panelist Commentary

February 9th 2023

Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.